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Summary 
Lipid droplet storage proteins (LSDPs) associate with lipid droplets and are involved 
in the molecular processes of deposition and catabolism of stored lipids in the cells. 
These proteins differ in tissue distribution, binding affinity to lipid storage droplets, 
protein stability and transcriptional regulation. Due to these differences, they are 
believed to have evolved to fine tune fatty acid metabolism according to the 
particular needs of various tissues. Recent knowledge reveals that these proteins are 
transcriptionally regulated by Peroxisome Proliferator-Activated Receptors (PPAR).  
In this thesis I have focused on the newly discovered protein, lipid storage droplet 
protein 5 (LSDP5), and the transcriptional regulation of this protein. Nebbs group has 
previously demonstrated in animal studies that LSDP5 is transcriptionally regulated 
by PPARα in liver. However, it has been difficult to prove through transfection 
studies that this regulation is mediated through a PPARα responsive DR1 element 
(PPRE). The main objective for this thesis was thus to establish whether there is a 
functional PPRE located in the LSDP5 promoter. Furthermore, the aims were to 
examine whether the transcriptional regulation of LSDP5 is affected by additional 
regulatory factors; the transcription factor estrogen-related receptor α (ERRα) and the 
coactivator PPARγ coactivator-1α (PGC-1α). 
In this study it was confirmed that LSDP5 contains a functional PPRE, located in the 
-2077base pairs (bp) to -2064bp upstream region in the LSDP5 gene. Furthermore, it 
was demonstrated that the PPARα mediated transcriptional regulation of LSDP5 is 
dependent on PGC-1α. PGC-1α enhanced the transcriptional activity in the LSDP5 
gene remarkably. ERRα repressed the expression of LSDP5. We observed that the 
presence of ERRα reduced the enhancing effect of PGC-1α on LSDP5 induction. 
Taken together, my data and the previously published data in our group confirm that 
LSDP5 is a PPARα target gene. Furthermore, our findings provide new aspects in the 
regulation of LSDP5, regarding the role PGC-1α and ERRα. 
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Sammendrag 
Lipiddråpe-assosierte proteiner (LDAP) er bundet til lipiddråper og involvert i 
molekylære prosesser som lagring og nedbrytning av lipider som er lagret i celler. 
Disse proteinene er ulike med hensyn til vevsekspresjon, bindingsaffinitet, 
proteinstabilitet og transkripsjonell regulering. Man antar at disse ulikhetene skyldes 
at proteinenes regulering av fettsyremetabolismen er spesifikt tilpasset ulike vev. 
Nyere kunnskap har vist at LDAP`ene er transkripsjonelt regulert av Peroksisomal-
Proliferator-Aktiverte Reseptorer (PPAR). 
I dette arbeidet har jeg fokusert på ”lipid storage droplet protein” 5 (LSDP5), et 
nyoppdaget LDAP, og hvordan dette proteinet er transkripsjonelt regulert. Det har 
tidligere blitt vist i Nebbs gruppe at LSDP5 er transkripsjonelt regulert av PPARα i 
lever. Det har imidlertid vært vanskelig å bevise gjennom transfeksjonsstudier at 
denne reguleringen skjer via et PPAR responselement (PPRE). 
Hovedproblemstillingen i denne oppgaven var derfor å undersøke om det er et 
funksjonelt PPRE i promoteren til LSDP5. Videre ønsket vi å undersøke om 
reguleringen av LSDP5 skjer i samspill med andre faktorer, nærmere bestemt 
transkripsjonsfaktoren estrogen-relatert reseptor α  (ERRα) og koaktivatoren PPARγ 
koaktivator-1α (PGC-1α). 
Resultatene fra dette arbeidet bekrefter at LSDP5 inneholder et funksjonelt PPRE, 
lokalisert -2077basepar (bp)  til -2064bp oppstrøms for transkripsjonsstart i LSDP5 
genet. Videre viser resultatene at den PPARα-medierte reguleringen av LSDP5 er 
avhengig av PGC-1α. Denne koaktivatoren økte den transkripsjonelle aktiviteten i 
LSDP5 genet betydelig. Når det gjelder ERRα, ble det observert at denne 
transkripsjonsfaktoren hemmet ekspresjonen av LSDP5. Det ser ut til at effekten av 
PGC-1α på ekspresjonen av LSDP5 blir betydelig redusert når ERRα er til stede. 
Disse resultatene gir et viktig bidrag til kunnskap om hvordan LSDP5 er 
transkripsjonelt regulert. Sammen med de tidligere publiserte resultatene fra 
dyreforsøk, bekrefter disse transfeksjonsstudiene at LSDP5 er et PPARα målgen. 
 10 
Resultatene i oppgaven bidrar også med nye aspekter i reguleringen av LSDP5, hvor 
vi nå har sett at PGC-1 og ERRα spiller en viktig rolle i kontroll av den 
transkripsjonelle reguleringen av LSDP5 genet. 
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1. Introduction 
The storage of energy excess when energy intake exceeds energy cost, and the release 
of energy in situations where energy access is limited characterize normal regulation 
of energy balance (1). Increased energy intake might result in an imbalance between 
fat synthesis and degradation, leading to an increase in circulating fatty acids (FAs) 
and accumulation of lipids in white adipose tissue (WAT). Whereas most tissues 
store excess FAs in the form of triacylglycerol (TAG), WAT has a unique capacity to 
store most of the body’s TAG reservoir in lipid droplets (2). The incorporation of 
FAs in TAGs is very important, as increased level of circulating FAs might cause 
harmful effects. Elevated plasma concentrations of FAs have been implicated in the 
etiology of insulin resistance and diabetes (3). However, increased accumulation of 
lipids in WAT often causes diseases and disorders. In the state of hyperlipidemi, 
accumulation of lipids exceeds the storage capacity of the WAT and lipids are 
distributed in non-adipose tissues such as skeletal muscle, cardiac myocytes and 
pancreatic β-cells, leading to cell dysfunction and possible cell death, a phenomenon 
called lipotoxicity (4). Whereas lipid accumulation in skeletal muscle is associated 
with the development of insulin resistance (5), lipid overload in β-cells leads to 
dysregulated insulin secretion (6). Lipotoxicity in heart might cause heart failure (7). 
This illustrates important aspects in lipid metabolism, and clarifies the consequences 
of a dysregulation in lipid metabolism. The molecular processes of deposition or 
catabolism of the stored lipid components is regulated by a complex system of 
hormones, transcription factors and other factors that associate with the lipids and 
mediate their function within the cell.  
 
.  
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1.1 Lipid droplet associated proteins (LDAPs) 
The ability to store large amounts of lipids is essential to ensure that energy is 
available in situations where energy access is limited, for instance during prolonged 
fasting. Fasting is a powerful stimulator of WAT lipolysis, which gives rise to a 
profound increase in plasma free FA (FFA) content. These FFAs are readily taken up 
by the liver or oxidized, converted to ketone bodies, or incorporated into lipid storage 
droplets (LSDs) (8). Most mammalian cells are able to store triacylglycerols (TAG), 
cholesterol esters or other lipids in these LSDs. The size of the droplets varies. While 
most cells store the lipids in relative small (< 1 μm diameter) storage droplets for use 
as energy source or in membrane biogenesis, the adipocytes contain large TAG-rich 
droplets that can exceed 50 μm in diameter. Thus, WAT has the capacity of highly 
efficient packaging of lipids (9). There is lack of knowledge about the mechanisms 
that control the flux of neutral lipids into and out of LSDs in any type of cell. LSDs 
are not just lipid depots, but also functional subcellular organelles. They are involved 
in multiple intracellular processes including lipid metabolism, vesicle traffic, and 
signalling through interactions with other organelles. This indicates that LSDs are 
important in lipid homeostasis (10-12). Different proteins are found on the surface of 
LSDs of basal and lipolytically stimulated 3T3-L1 cells (13) , some are ubiquitously 
expressed as stomatin; a raft associated protein (14), others are tissue specific 
expressed as α-synuclein in neurons (15) and stanniocalcin in ovary (16). Caveolins 
which also are proteins targeted to LSDs, are assumed to play important roles in 
signal transduction, cholesterol transport and endocytosis (17). 
The lipid droplets consist of a core of neutral lipids, surrounded by a monolayer of 
phosholipids, into which proteins are embedded (18;19)  
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Among proteins that are found to co-localize on the LDSs surface are proteins 
involved in LSD coating. These proteins play an important role in the molecular 
processes that govern either the deposition or catabolism of the stored lipid 
components in the LSDs (20). The first protein to be experimentally identified to 
associate with the LSD surface was perilipin (21) Soon thereafter, ADRP (Adipose 
Differentiation-Related Protein) /adipohilin (22), TIP47 (Tail-interacting protein of 
47 kDa)/placental tissue protein 17 (pp17) (23), S3-12 (24) and LSDP5 (25)  were 
identified. 
1.1.1 Structure 
Perilipin, ADRP and TIP47 exhibit high sequence identity within an amino-terminal 
PAT-1 domain and a weaker homology in the central and carboxyl-terminal PAT-2 
domain (26) (Figure 1.1). Due to their structural similarities, these proteins have been 
named the PAT-family (Perilipin-ADRP/adipophilin/TIP47). Adipohilin is the 
human ortholog of ADRP (27). S3-12 shares significant sequence homology to 
ADRP and TIP-47 in the carboxyl-terminus, but limited identity with the PAT-1 
domain. It is therefore considered as a peripheral member of the PAT-family. LSDP5 
is a recently identified member of the PAT-family. Structurally, it shares highest 
homology with TIP47 and ADRP. It is related to perilipin with sequence similarity 
within the amino-terminal PAT-1 domain region and the 11-mer repeated region. The 
homology to S3-12 is restricted to a sequence after the PAT-1 domain (28). Common 
for all the PAT-proteins is a segment of 11-mer helical repeats in the central 
sequence. This 11-mer repeat is responsible for the binding to the LSD surface, by 
forming an α11/3 amphipatic helix conformation enabling the hydrophobic and non-
hydrophobic amino acids to be positioned on opposite half-sites of the alpha helix 
and thereby facilitate lipid association (29) (Figure 1.2 ).  
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Figure 1.1 A schematic drawing of sequence identity (and similarity) of mouse LSDP5 against 
the other PAT members. Overall, LSDP5 is highly identical in sequence to TIP47 and ADRP (from 
aa 33 to 401) with 36 and 32 percent sequence identity (70 and 71 percent similarity), respectively. 
All PAT members have unique extreme amino- and carboxy- termini of varying sizes. LSDP5 has 
considerably longer unique N- and C-termini compared to the more related PAT members TIP47 and 
ADRP (Adapted from (30)). 
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Figure 1.2 Helical pinwheel plot. The 11-mer helix contains hydrophobic amino acids shown on the 
upper side of this pinwheel plot and polar amino acids on the other side. This structure might give 
LSDP5 both lipid binding and hydrophilic properties. Hydrophobic residues are in black, charged 
residues in red or blue, and polar residues in yellow. 11-mer repeat: HxxHxxxHxxx, where H is 
hydrophobic and x are non-hydrophobic residues. Adapted from (31). 
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1.1.2 Tissue expression  
The LDAPs are expressed in distinct tissues, suggesting that they have evolved to 
fine tune lipid metabolism according to the particular needs of these tissues. Perilipin 
is found only on the TAG-rich LDs in adipocytes and the cholesterol ester-rich 
droplets in steroidogenic cells (32). S3-12 is highly expressed in adipose tissue, 
skeletal muscle and heart (33;34). Originally, ADRP was thought to be mainly 
expressed in adipocytes, but later it is found that ADRP is ubiquitously expressed, 
with specifically high expression in metabolic organs and tissues (35). ADRP 
associates with smaller neutral LDs located within most tissues, but rarely in adipose 
cells that express perilipin. TIP-47 is ubiquitously expressed. However, a higher 
expression in skeletal muscle and placenta has been observed (36) According to the 
newly published data by Dalen et al, LSDP5 is found to be mainly expressed in fatty 
oxidising tissues and organs such as heart, liver and red muscle (37). These findings 
are confirmed in another study, performed by Yamaguchi et al (38). The high 
expression of LSDP5 in muscle is confined to red muscle (M-soleus) (39) (Figure 
1.3). 
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Figure 1.3 Tissue expression of LSDP5 in human and mouse tissues. (A) Expression of LSDP5 
mRNA in human tissues. Expression of PPARα and RXRα is shown for comparison. (B) Expression 
of LSDP5 mRNA in mouse tissues (C57/BL strain). Expression of PPARα and RXRα is shown for 
comparison. For both blots, the most abundant expressed transcript (2.5 kb) is in agreement with the 
predicted mRNA transcript size. Additional uncharacterized transcripts are observed in human liver 
(~5 kb) and in specific mice tissues (~2 kb). Adapted from (40). 
1.1.3 Function 
Earlier the LSDs were regarded as simple lipid reservoirs (41). Recent knowledge 
demonstrates that they are active intracellular compartments involved in lipid 
metabolism, by affecting the lipogenetic and lipolytic processes in the body (42) . To 
date, the function of perilipin is best established. 
The main function of perilipin is to protect the LSDs from lipolysis, by preventing 
access of hormone-sensitive lipase (HSL) to the lipid droplet. Perilipin is a major 
substrate of cAMP-dependent protein kinase in adipocytes. When perilipin is 
phosphorylated as a result of hormonal stimulation, HSL gets access to the lipid 
droplet and initiates lipolysis. Studies with perilipin knockout mice show that these 
mice have a constitutive lipolysis, normal bodyweight despite an increase in food 
consumption, smaller fat depots and they are resistant to diet-induced and genetic 
obesity (43).  
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Originally, ADRP was thought to be mainly expressed in adipocytes, based on 
observations of increased ADRP mRNA expression during adipocyte differentiation. 
Recent studies however show that ADRP has a specialized role in the liver where it 
associates with TAG-rich LSDs. ADRP ensures that FFAs, released from peripheral 
tissues during fasting, efficiently are incorporated in the LSDs. This is crucial to 
prevent high levels of FFA in the liver (44).  
The knowledge upon the function of TIP47 is limited. So far, we know that it 
associates with small LSDs (45). A more specific biological role remains to be 
clarified.  
S3-12 coats nascent LSDs in adipocytes during TAG synthesis, and might play a role 
in FA uptake or de novo TAG synthesis (46).   
Dalen et al proved that LSDP5 binds to the surface of LSDs, in the similar manner as 
the other PAT-proteins (47) (Figure 1.4) . With broadest expression in tissues with 
high fatty oxidising capacity such as heart, liver and skeletal muscle, it is suggested 
that LSDP5 plays an important role in oxidation of fatty acids (48).  
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Figure 1.4 LSDP5 selectively associates with the lipid storage droplet surface. Cos-1 cells were 
transfected with pEYFP-C1-vector or YFP-fused to cDNA coding for LSDP5 or perilipin and 
incubated with BSA or BSA-bound oleic acid (OA) (100µM) for 24 hours. The cells were fixed with 
paraformaldehyde/glutaraldehyde prior to staining of lipids with Oil Red O. Cellular localization of 
PAT proteins was determined with immunofluorescence confocal laser microscopy. Left panels show 
immunofluorescent signal (green), middle panels show Oil red O staining (red), and right panels 
show merged images.(A) Expression of YFP-LSDP5 in cells incubated with BSA.(B)Expression of 
YFP, YFP-LSDP5 and YFP-perilipin in cells incubated with OA-BSA. Adapted from (49). 
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Recent data indicates that ADRP (50) TIP-47 (51) and LSDP5 (52) in addition to 
perilipin, play an important role in protecting the stored lipids from degradation by 
coating of LSDs. Thus, coating of LSDs to prevent lipolysis, seems to be a common 
feature for the PAT-proteins. This role has not been found for S3-12.    
1.2 Transcriptional regulation of the LDAPs 
In the organism there are numerous factors involved in transcription of genes 
controlling metabolism. These transcription factors (TFs) constitute about 3000 of all 
30000 protein coding genes in the human genome which indicates a complex and 
tight regulation of metabolic control (53). The expression of genes is dependent on 
TF binding to specific DNA sites, response elements (RE), in the regulatory area 
(promoter) of target genes (54). The promoter is localized in front of the coding 
sequence of a gene which consist of a transcription initiation site and often a TATA 
box (thymidine and adenine rich motif) and/ or an initiator element that facilitate the 
assembly of the general transcription factors (GTFs) required for specific promoter 
binding by RNA polymerase II (54-56).  
Several of the PAT genes are transcriptionally regulated by members of the PPAR 
family such as S3-12, perilipin, ADRP and LSDP5. This will be described 
underneath.  
1.2.1 PPARs  
PPARα, δ and γ are members of the nuclear receptor (NR) superfamily of ligand-
dependent transcription factors (Figure 1.5) (57).  
1.2.1.1 Nuclear receptors  
Nuclear receptors (NRs) regulate the expression of target genes to affect processes as 
diverse as reproduction, development, and general metabolism. These proteins were 
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first recognized as the mediators of steroid hormone signalling and provided an 
important link between transcriptional regulation and physiology. Today, the human 
genome is reported to contain 48 members of this superfamily (58). The family 
includes not only the classic endocrine receptors that mediate the actions of steroid 
hormones, thyroid hormones, and the fat-soluble vitamins A and D, but a large 
number of so-called orphan nuclear receptors, whose ligands, target genes, and 
physiological functions were initially unknown. Today this last group is divided into 
two; the adopted orphan receptors, where the physiological ligand is now known, and 
the orphan receptors where the physiological ligand is still unknown. Members of the 
adopted orphan receptor group, also named “sensor receptors”(59) ,  include e.g. 
receptors for fatty acids; PPARs, oxysterols; liver X receptor (LXRs), bile acids; 
farnesoid X receptor (FXR) and vitamin A; retinoid X receptor (RXR) (60) (Figure 
1.5). 
 
Figure 1.5. The nuclear receptor super family. The classic hormone receptors bind molecules with 
a high affinity. As key factors of endocrine homeostasis, their activation is associated with many 
metabolic adjustments. The “sensor” receptors are sensors of the metabolic status, respond to both 
incoming dietary signals and metabolites generated in the organism, and are responsible for the 
metabolic adaptation at the cell, organ, and whole organism level. The orphan receptors possess the 
structural characteristics of nuclear receptors including a sequence consistent with the presence of a 
ligand binding domain. No ligand has thus far been identified for these receptors. Adapted from (61) 
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The protein structure of the NRs consists of several domains. At the NH2- terminal 
region there is a ligand-independent transcription activation function domain (AF-1 
or A/B domain). In the core, a DNA-binding domain (DBD or C domain) is located 
which contains two highly conserved zinc finger motifs that target the receptor to 
specific DNA Response elements (RE). A hinge region (D domain) permits protein 
flexibility to allow for simultaneous receptor dimerization and DNA binding. 
Adjacent to the hinge region there is a large ligand-binding domain (LBD or E/F 
domain) that mediates ligand binding, dimerization, interaction with heat shock 
proteins, nuclear localization and  transactivation. At the COOH-terminal region, the 
AF-2 domain binds co-repressor or co-activator (Figure 1.6A) (62). NRs bind to 
specific REs at their respective target genes that consist of one or two consensus core 
half site sequences in the promoter or enhancer region. Binding of the NR occurs 
either as a monomer, homodimer or a heterodimeric complex with another NR; often 
with the receptor for 9-cis-retinoic acid known as RXR to the consensus sequence, 
AGGTCA. The consensus sequences are arranged as direct-(DR), inverted- (IR) or 
everted (ER) repeats separated by 1-6 nucleotides (n) (Figure 1.6B). When a ligand 
binds a specific NR, the receptor undergoes a conformational change (Figure 1.6C); 
co-repressors dissociate which further lead to recruitment of co-activators that enable 
transcriptional activation (Figure 1.6 D). 
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Figure 1.6 Nuclear Receptors as Ligand-Dependent Transcription Factors. Panel A shows the 
canonical structure of the nuclear receptor, which includes N-terminal activation function 1 (AF1), 
DNA binding, ligand binding, and C-terminal AF2 domains. Responsive elements in the nuclear 
receptor can be configured as either direct, inverted, or everted repeats of the hexad core sequence 
AGGTCA (Panel B). The number of nucleotides between the two core elements (n) confers 
additional specificity. As shown in Panels C and D, RXR heterodimers constitutively bind to 
response elements in the promoter regions of target genes. In Panel C, in the absence of agonist 
ligand, the AF2 domain conformation promotes receptor interaction with co-repressors. The 
multiple-subunit co-repressor complex stabilizes repressive local chromatin structure and blocks 
access of the transcription machinery (red X) to the promoter. As shown in Panel D, ligands diffuse 
across the nuclear membrane and bind to receptor ligand-binding domains. Ligand binding triggers a 
conformational change in the AF2 domain, which destabilizes co-repressor interaction and promotes 
co-activator binding. Multiple-subunit co-activator complexes activate local chromatin structure and 
recruit the transcription machinery to the promoter, where target-gene transcription commences. 
Adapted from (63). 
 24 
The PPARs transcriptional regulates their specific target genes by binding to a PPRE 
located in the regulatory area of the gene (figure 1.7). This DNA element is a  DR1 
(for some genes a DR2 element) which means that the RE consists of a direct repeat 
of the consensus sequence, AGGTCA half site spaced by one (or two) nucleotides 
(64).  
Activation of PPAR
Increased 
transcription of 
gene
PPRE
9-cis RA Fatty acid, PP
Co-activator
RXR PPAR
TATAAT
5’-CCAGGGGTCAAAGTTCATCAG-3’
DR1 element
 
Figure 1.7: When PPAR is activated by ligands, PPAR heterodimerizes with RXR and regulate 
transcription by binding to a specific PPAR response element (PPRE) in the promoter in the target 
gene.  
 
 A common feature among a few of the NR members is that they transcriptional 
regulate their target genes as heterodimers with retinoid X receptors (RXRs). The 
NRs are activated by specific ligands, where they bind to their ligand binding 
domain. PPARs are activated by fatty acids, naturally occurring fatty acid-derived 
molecules and synthetic ligands (65). The PPARs are important pharmacological 
targets for treatment of obesity, diabetes and lipid disorders.  
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The PPARs include three different isoforms designated PPARα, PPAR β/δ and PPAR 
γ. Although all three isoforms share similar protein sequence and structure, they 
differ in tissue distribution, ligand selectivity and biological actions. Figure 1.8 gives 
and overview over the signalling pathways the PPARs regulate and how their 
metabolic pathways integrate.       
 PPARα is expressed in tissues with high β-oxidation activity corresponding to its 
role in regulating the oxidation of FAs (66), such as liver, brown adipose tissue, 
muscle, heart and kidney. Thus, the main role of PPARα is to transcriptional regulate 
genes that are involved in lipid and lipoprotein metabolism (67). Furthermore, 
PPARα is irreplaceable for a proper response to fasting in liver (68).  PPARα ligands 
are polyunsaturated fatty acids, including DHA and EPA, oxidised phospholipids, 
lipoprotein lipolytic products and fibrates (69).   
PPARγ is highly expressed in WAT and macrophages. PPARγ ligands are naturally 
occurring FA derivatives, prostaglandin derivatives and synthetic compounds such as 
the antidiabetic thiazolidinediones (TZDs). By acting as direct agonists for PPARγ, 
these drugs reduce peripheral insulin resistance and thus lower blood glucose levels 
in patients with type 2 diabetes. The activation of PPARγ results in a reduced release 
of FFAs and insulin resistance-mediating adiopocytokines, such as tumor necrosis 
factor α (TNFα), leptin or resistin, and an increased production of the antidiabetic 
adiponectin. The consequence of this is improved insulin sensitivity in liver and 
skeletal muscle (70). The high expression of PPARγ in WAT is linked to its role as a 
crucial regulator of the adiopogenesis, the process of preadipocytes maturing into 
adipocytes (71). 
 PPAR β/δ is ubiquitously expressed. It is activated by polyunsaturated FAs 
(PUFAs), prostaglandins and synthetic compounds. Similar to PPARα, PPAR β/δ 
plays an important role in the regulation of glucose and lipid levels in plasma, by 
stimulating FA oxidation in heart and skeletal muscle. Treatment with PPAR β/δ 
agonists in obese phenotype db/db mice, normalized the lipid profile and reversed 
diet-induced obesity and insulin resistance in mice (72). 
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Figure 1.8 Metabolic integration by PPARs. The three PPAR isoforms regulate lipid and glucose 
homeostasis through coordinated activities in liver, muscle and adipose tissue. Adopted from (73) 
 
 
1.2.2 PPARs regulate the transcription of LDAPs  
The tissue expression of PPARs is closely related to the expression of the LDAPs, 
and recently published studies confirm that the distinct members of the PAT-family 
are transcriptionally regulated by the PPARs (74). 
S3-12 and perilipin have been demonstrated to be PPARγ target genes in WAT (75). 
In a study performed by Dalen et al (2), it was shown that these promoters of the 
genes contain an evolutionary conserved PPRE. They also found that S3-12 and 
perilipin are induced during adipocyte differentiation, matching the timing of PPARγ 
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induction, and induced by PPARγ activation (76). The function of S3-12 and 
perilipin in WAT are believed to be their involvement in storage of lipids in LSDs by 
stimulating uptake of FAs and de novo TAG-synthesis (S3-12) and by preventing the 
release of FAs from the lipid droplets (perilipin). 
TIP47 has not yet been demonstrated to be regulated by PPARs. 
While S3-12 and perilipin are regulated by PPARγ in WAT, it has recently been 
demonstrated that ADRP is regulated by PPARα in liver (77). This regulation is 
mediated through a highly conserved DR-1 element. Both in vitro and in vivo studies 
have shown that PPARα activation by the synthetic ligand WY-14643 induces the 
expression of ADRP (78). Along this line, a functional PPRE was identified both in 
the human adipophilin and mouse ADRP promoters. Recent findings by Dalen et al 
(79) furthermore demonstrated that the expression of ADRP is stimulated by fasting 
in the liver in vivo. Based upon the knowledge that the expression of PPARα is also 
induced during fasting and its target genes, it was therefore reasonable to believe that 
the upregulation of ADRP during fasting is due to PPARα activation. However, 
surprisingly, studies with PPARα knockout mice demonstrated that the expression of 
ADRP during fasting is independent of PPARα (80), suggesting that ADRP is 
regulated by other mechanisms during fasting. This is opposite from ADRP gene 
regulation by PPARα agonists as discussed above. The accumulation of ADRP and 
the formation of LSDs are highly correlated (81): fasting and the presence of FAs 
facilitate formation of LSDs and increased formation of LSDs results in a higher 
cellular content of ADRP. When ADRP is not bound to LSDs, it is rapidly degraded 
by proteasomes (82). The main function of ADRP in liver is to ensure that FAs 
released from peripheral tissues during fasting, are incorporated in the TAG-
containing LSDs.  
 
The knowledge upon regulation of the newly identified LSDP5 is still limited, but so 
far studies indicate that it is regulated by PPARα and that the regulation of the 
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LSDP5 gene is, at least in part, similar to the regulation of the ADRP gene (83). Like 
ADRP, LSDP5 is induced during fasting, independently on a functional PPARα. 
However, the basal expression of LSDP5 is dependent upon PPARα. This was 
demonstrated in PPARα wild-type mice and PPARα knockout mice (84).  
Despite these findings indicate that LSDP5 is transcriptionally regulated by PPARα, 
it has so far not been confirmed that the LSDP5 gene contains a functional conserved 
DR-1 element.  
1.2.3 New aspects in PPARα regulation of LDAPs 
Recently, transcriptional regulation of PPARα target genes has been related to two 
other proteins that are demonstrated to have an important influence on the regulation 
of PPARα target genes. Estrogen-related receptor α (ERRα) and PPARγ coactivator-
1α (PGC-1α) are both involved in regulation of genes involved in energy production 
pathways, including cellular FA uptake, FA oxidation and mitochondrial electron 
transport/oxidative phosphorylation.  
ERRs are orphan NRs, and consist of three isoforms, ERRα, ERRβ and ERRγ (85). 
ERRα and ERRγ are predominantly expressed in highly active metabolic tissues such 
as BAT, heart and skeletal muscle (86). These tissues use primary FAs as energy 
substrate. After birth, the expression of ERRα in heart increases dramatically, 
coincident with the postnatal switch to FAs as energy substrate (87). This 
demonstrates ERRα`s function in FA oxidation in heart. It is found that ERRα 
regulates the expression of medium-chain acyl coenzyme A dehydrogenase (MCAD), 
which is a key enzyme in the FA β-oxidation pathway in the mitochondria (88). 
However, the ERRα mediated gene regulation of MCAD, seems to be dependent on 
the coactivator, PGC-1α. Early attempts to prove ERRα`s role in transcription of 
MCAD failed without the presence of this coactivator (89). PGC-1α belongs to the 
PGC-1 family along with the two other isotypes, PGC-1β and PGC-related 
coactivator (PRC) (90). The expression of PGC-1α is most prominent in tissues with 
high energy demands (91), similar to the expression pattern of ERRα. PGC-1α is a 
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key regulator in cellular energy metabolic pathways, where it primary regulates FA 
oxidation and increases the number of mitochondria (92). 
Originally, PGC-1α was identified as a PPARγ-interacting protein in BAT, from 
which the term PPARγ coactivator-1α is adopted (93). To date, it is known that it 
interacts with many different transcription factors, including PPARα and ERRα (94).  
Coactivators play an important role in gene regulation. PGC-1 coactivators have 
powerful transcriptional activity when linked to a DNA binding domain or when they 
dock on a transcription factor (95) (Figure 1.6 D). They bind a protein complex with 
histone acetyl transferase (HAT)-activity at the amino-terminal region. The HAT-
containing proteins acetylate histones and remodel chromatin structure to allow 
transcriptional activity. When PGC-1α is bound to this activation complex, repressor 
proteins such as histone deacetylase and small heterodimer partner (SHP) is replaced 
and this results in increased transcription (96).  
 The importance of this coactivator in oxidative metabolism pathways is 
demonstrated in animal studies. In PGC-1α knockout mice it is demonstrated reduced 
mRNA expression of genes involved in mitochondrial oxidative metabolism in 
tissues such as heart, liver, BAT and skeletal muscle. PGC-1α is required for the 
normal expression of these genes.  
Both ERRα and PGC-1α are involved in the same metabolic pathways as PPARα. It 
is also shown that the ERRα mediated regulation of the FA utilization genes occurs 
through direct activation of PPARα gene transcription (97). Several of the genes 
involved in FA catabolism that ERRα and PGC-1α regulates, are target genes of 
PPARα. It is therefore interesting to consider whether the PPARα mediated 
regulation of LDAPs might be influenced by ERRα and PGC-1α.    
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2.  Objectives 
The main objective in this project was to study the transcriptional regulation of 
LSDP5. Recent studies indicate that LSDP5 is a PPARα target gene. However, it has 
been difficult to show through transfection studies that the LSDP5 promoter contains 
a functional PPRE. In this thesis I wanted to examine whether the LSDP5 gene 
contains a PPRE in addition to study whether the PPARα mediated regulation of 
LSDP5 is influenced by additional regulatory proteins.  I have focused on the NR 
ERRα and the coactivator PGC-1α. 
Following sub-objectives were addressed;  
• Does the LSDP5 gene contain a conserved PPAR response element? 
• Does PGC-1α enhance the transcriptional activity of the LSDP5 gene? 
• Is the PPARα mediated regulation of LSDP5 affected by ERRα? 
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3. Materials and methods 
3.1 Materials 
   
Bacteria Manufacturer  
   
Competent E.coli Invitrogen  
   
Cell lines Manufacturer  
   
Monkey kidney COS-1 cells ATCC  
   
Cell medium Manufacturer  
   
Dulbecco`s Modified Eagle`s Medium (DMEM) Sigma  
Fetal Calf Serum Sigma  
   
Chemicals Manufacturer  
   
Ampicillin Sigma  
Bacto-Agar Merck  
Bacto-peptone Merck  
Bacto-yeast Merck  
CaCl2 Merck  
Coenzyme A Sigma  
Dextrose Sigma  
DTT (DL-Dithionthreitol) Sigma  
EDTA (ethylenediaminetetraacetic acid) Sigma  
Ethanol Merck  
Glucose Sigma  
Glycerol Fluka  
HCl Chemi-teknikk AS  
Hepes (Hydroxyethylpiperazineethanesulfonic acid) Sigma  
Isopropanol Arcus  
KCl Merck  
KH2PO4 Merck  
L-glutamine Merck  
Luciferin Sigma  
Lysis buffer x 5 Promega  
MgSO4 x 7H2O Sigma  
MgSO4 Sigma  
Na2HPO4x2H20 Merck  
NaCl Sigma  
NaH2PO4 Merck  
NaOH Chemi-teknikk AS  
PBS (Phophat buffered saline) Gibco  
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Pencillin/Streptomycin Sigma  
Trypsin BioWhittaker  
WY-14.643 Sigma  
9-cis-retinoic acid Sigma  
   
Equipment Manufacturer  
   
Cell flasks and plates Corning Incorporated  
Falcon tubes Falcon  
Microtubes Sarsted  
Parafilm American National Can  
Pipettes Biohit  
Pipette tips Integra bioscenses  
96-well plates Sigma  
Pipeteboy Comfort Integra bioscenses  
   
Instrument Manufacturer  
   
Biofuge fresco (Centrifuge) Heraeus instruments  
Cell counter model Z1 Coulter electronics  
Freezer, -20 C Forma Scientific  
Incubator Forma Scientific  
Luminometer TD-20/20 Turner design  
MilliQ-synthesis Millipore  
   
Kits Manufacturer  
   
Jet Star Maxiprep Kit Genomed  
BC Assay Protein quantitation kit Uptima  
   
Plasmids   
   
pGL3-mLSDP5-luc   
pCMX-hERRα   
pcDNA3-mPGC-1α   
pSG5-mPPARα   
pSG5-mRXRα    
   
Software and internet resources Manufacturer  
   
Adobe Illustrator Adobe Incorporated  
Microsoft Office 2003 Microsoft Incorporated  
Pubmed National Library of Medicine  
Reference Manager 10 ISI Research Soft  
SPSS 14.0 SPSS Incorporated  
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3.2 Methods 
In order to study if PPARα regulates the transcriptional activity of the LSDP5 gene, 
the LSDP5 promoter was characterized with respect to whether PPARα and its 
heterodimer, RXR as well as ERRα and PGC-1α are able to induce the 
transcriptional activity of the LSDP5 gene. To study this, an LSDP5 reporter 
construct (pGL3-(m)LSDP5-Luc [-2324 to +244]) was cotransfected  with following 
expression plasmids ERRα, PPARα, RXRα and PGC-1α (alone or together) into Cos-
1 cells. After this transient transfection the cells were harvested and transcriptional 
activity was measured by the Luciferase assay. 
3.2.1 Culturing and seeding cells 
Monkey kidney Cos-1 cells (ATTC # CRL-1650) were cultured in high glucose (4,5 
g/L) containing Dulbecco`s modified Eagle`s medium (DMEM, Sigma; #6546) 
supplemented with 10 % heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 
penicillin (50 U/ml) and streptomycin (50 μg/ml) at 37 C in 5 % CO2.  Cells were 
kept subconfluent prior to experiments. 
The cell number was quantified using the Coulter Counter. 
The day before transfection, the cells were seeded at 90 % confluency in six-well 
plates, 200 000 cells per well.    
3.2.2 Transformation of plasmids into bacteria 
Before transfecting the cells with reporter plasmids and expression plasmids we had 
to produce a large amount of each plasmid by using bacteria that are able to copy the 
DNA plasmids very fast (Figure 3.1). The plasmids behave as accessory genetic units 
that replicate and are inherited independently of the bacterial chromosome.  
 34 
 
Figure 3.1A: Schematic drawing of a bacterium with plasmids enclosed. 1: 
Chromosomal DNA. 2: Plasmids. (Adapted from Wikipedia). 
 
 
 
 
Figure 3.1B: Schematic drawing of a plasmid with antibiotic resistances. 1 & 2 Genes that 
code for resistance. 3 Origin of replication, or Ori (a starting point for DNA replication). 
(Adapted from Wikipedia). 
 
Transformation is an artificial process where plasmid DNA is introduced into 
bacteria. By growing the bacteria, the inserted plasmid vector will replicate, and it is 
possible to obtain high concentrations of the plasmid DNA. Plasmid vectors contain 
genetic markers, and these markers provide specific resistance to antibiotics such as 
the kanamycins, ampicillin and the tetracyclines. Selection of transformed bacteria is 
therefore possible by growing the bacteria in medium with specific antibiotics (figure 
3.2) (98). 
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Figure 3.2: The transformed bacteria, containing the ampicillin-resistance gene, are 
grown overnight, and this results in ampicillin-resistant colonies in the agar plates.  
 
3.2.3 Plasmids  
The plasmids used in this project were available in the laboratory prior to initiation of 
the transfections; The pCMX-mERRα (gift from Prof. Vincent Giguere, Molecular 
Oncology Group, McGill University Health Centre, Canada), pcDNA3-mPGC-1α 
(gift from Prof. Vincent Giguere, Molecular Oncology Group, McGill University 
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Health Centre, Canada), pSG5-mRXRα and pSG5-mPPARα expression vectors 
(provided by Jan-Åke Gustafsson (Department of Bioscience and Medical Nutrition, 
Novum, Huddinge, Sweden)) have been described previously. The pGL3-(m)LSDP5-
Luc reporter vectors were generated as described below. 
Identification, cloning and mutagenesis of the LSDP5 promoter were made as follow 
by Post.Doc Knut Tomas Dalen: The full-length mouse LSDP5 cDNA sequence was 
used to search nonredundant and high-throughput genomic sequence databases by the 
basic local alignment search tool (BLAST) to identify the LSDP5 promoter sequence. 
The sequence spanning the transcription start site (-4000 to +2000) was scanned with 
a consensus PPRE (RGGBSAAAGGTCA) with the use of the gcg program package. 
The full-length mouse LSDP5 promoter (pGL3-(m)LSDP5-Luc [-2324 to +244]) was 
amplified with PfuTurbo (Stratagene) with mouse genomic DNA (Clontech, #6650-
1) as template using PCR-settings as described (99). Primers used: 
5-m-LSDP5-promoter (HindIII): 5'-
TAAAGCTTGCCAGGAATGCTATTCTCGGACT-3', 
3-m-LSDP5-promoter (HindIII): 5'-
TAAAGCTTTCAGGGCTCATGCCCTATGTATC-3',  
The full-length mouse promoter (pGL3-(m)LSDP5-Luc [-2324 to +244]) was next 
inserted into a pGL3-Basic-Vector (Promega # E1751) as described (Appendix, 
Protocol 1). 
The deletion construct was generated by restriction digestion with SacI followed by 
religation of the vector to generate the pGL3-(m)LSDP5-Luc [-1329 to +244] vector. 
Site-directed mutagenesis of the DR-1 element to generate the pGL3-(m)LSDP5-Luc 
[-2324 to +244-DR-1 mut] was performed with site-directed mutagenesis as 
described (25). Oligos used: m-LSDP5-PPRE-s-mut: 5’-
GAGCCTGTGGACGTCAGACGGCTCCTTGCAGGA-3’ and m-LSDP5-PPRE-a-
mut: 5’-TCCTGCAAGGAGCCGTCTGACGTCCACAGGCTC-3’. 
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The plasmids were transformed into competent DH5α-E.coli bacteria according to 
the protocol (Protocol 2).                                                                                                                       
 
Protocol 2 
Solutions 
LB-medium is a growth medium with optimized growth conditions. LA-medium is 
LB-medium supplemented with bacteria agar, allowing the growth medium to be 
solid in dishes.   
LB medium  
To 2 L of distilled water, add: 20 g peptone, 10 g yeast extract, 20 g NaCl. Adjust the 
pH to 7.0. The solution is autoclaved to be sterilized.  
LA medium 
Add 1.5 % Bact agar to the LB medium. The solution is autoclaved to be sterilized.  
Agar plates 
After autoclave, allow the LA medium to cool to 50°C. Add 500 μl ampicillin (50 
mg/ml) to 500 ml LA-medium. Distribute the LA medium on plates. 
 
 
Experimental procedure 
Bacteria are stored at -70°C. Thaw the cells on ice. Use a sterile pipette tip to transfer 
100 μl of the competent cells to polypropylene tubes. Store the tubes on ice. (Glass 
tubes should not be used as they lower the efficiency of transformation by 10-fold). 
Add 2 μl plasmid diluted to a concentration of 10 ng/μl to the bacteria. Swirl the 
 38 
tubes gently several times to mix their contents. Store the tubes on ice for 60 minutes. 
Transfer the tubes into a preheated 42°C circulating water bath for 60 seconds. This 
step is called “heat shock” and is necessary for the pores in the bacteria membrane to 
open. Now it is possible for the DNA to be inserted into the bacteria. Then, rapidly 
transfer the tubes back to ice and allow the cells to cool for at least 2 minutes. This 
step is crucial to ensure that the pores close and that the DNA is kept inside the 
bacteria. Transfer 30 μl of the transformed cells onto agar plates. Sterilize a bent glass 
rod by dipping it into ethanol and then in flame of a Bunsen burner. When the rod has 
cooled to room temperature, spread the transformed cells gently over the surface of 
the agar plate, containing 50 μg ampicillin/ml. Incubate the plates over night at 37°C.  
Include a negative control: Add cells without inserted DNA onto an agar plate with 
ampicillin. No bacterial colonies should grow on this plate ((98), modified 
procedure).  
3.2.4 Bacterial growth 
After plasmids were transformed and bacteria were incubated overnight at 37°C, 
bacteria colonies were grown in the plates. Then one of these colonies was picked 
and transferred to a flask with LB-medium according to the protocol (Protocol 3). 
Next day, E.coli cells were grown to log phase.  
 
Protocol 3 
 
Experimental procedure 
Pick a single colony (2-3 mm in diameter) from the agar plate, and transfer the colony 
into a bottle with 100 ml LB-medium, supplemented with 50 μg ampicillin/ml. 
Incubate overnight at 37°C in an orbital incubator. Include a negative control: prepare 
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a small tube with only medium and ampicillin (2 μl ampicillin and 2 ml medium). No 
bacteria culture is expected in this tube. 
 
3.2.5 Isolation of plasmids 
After transformation of plasmids into bacteria and growing them overnight, the next 
step is to isolate the plasmids from the bacteria. This is obtained by centrifugation of 
the bacteria and then purifying the plasmids from the bacteria pellet. Maxi 
preparation of DNA is used for isolation of large amounts of highly purified plasmid 
DNA. The technique is based on the principle that the bacteria are lysated and 
neutralized. Then the lysate is applied onto a column and the DNA is bound to the 
anion exchange resin. Washing the resin removes RNA and all other impurities. 
Finally the purified plasmid DNA is eluted from the column and concentrated by an 
alcohol precipitation (Jet Star Protocol). In this project, plasmid isolation was 
performed according to the Jet Star Maxi protocol (Appendix, Protocol 4). 
 
Solutions 
Jet Star Maxi prep kit (GENOMED GmbH, # 220020) 
Isopropanol 
Ethanol, 70% 
 
Experimental procedure 
E.coli cells are pelleted by centrifugation. Transfer the bacteria to centrifugation 
tubes. Centrifuge at 5000 rpm for 10 minutes at 4 °C, and remove the supernatant.  
All traces of medium should be removed carefully. Then follow the steps in the Jet 
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Star Maxi Prep protocol (Appendix, protocol 4). Dissolve the precipitated plasmids in 
300 μl MilliQ H2O, and quantify DNA concentration on a photometer prior to 
transfection of plasmids into Cos-1 cells.  
3.2.6 Transfection, harvesting and lysis 
Transfection is introduction of cloned DNA into cultured eukaryotic cells. There are 
different strategies to deliver genes into eukaryotic cells, and the choice of method 
depends on several factors, such as the ability of cell line to survive the stress of 
transfection and the efficiency required of the system. There are three categories of 
transfection techniques: transfection by biochemical methods, transfection by 
physical methods, and virus-mediated transduction.  
The calcium-phosphate-mediated method is one of the biochemical methods and has 
been used for more than 30 years. It was originally presented by Graham and Van der 
Eb in 1973 (100), and is based on the principle that the uptake of DNA by cells in 
culture is markedly enhanced when the nucleic acid is presented as a coprecipitate of 
calcium phosphate and DNA. The calcium phosphate DNA-coprecipitate attaches to 
the cell surface and is absorbed by endocytosis. After entering the cells by 
endocytosis, some of the coprecipitate escapes from endosomes or lysosomes and 
enters cytoplasm, from where it is transferred to the nucleus. This results in 
expression of the transfected genes in up to 50 % of the cells (98). 
In this project, a reporter plasmid, the pGL3-LSDP5(-2324/+244)luc or the 5’-
deletion constructs of the LSDP5 promoter described above, was cotransfected with 
the expression plasmids for either pCMX-hERRα, pcDNA3-mPGC-1α, pSG5-
mRXRα and pSG5-mPPARα expression vectors, by the calcium-phosphate-mediated 
method (Protocol 5). The expression plasmids were added to investigate both the 
effect of them individually, and in combination with the other expression plasmids. 
An empty vector, pGL3-Basic-Vector (without LSDP5 inserted), was added to ensure 
equal concentrations of DNA in all wells. Cells were treated with a PPARα and a 
RXRα agonist, WY 14.463 (Sigma, # C7081) and 9-cis retinoic acid (9-cis-RA) 
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(Sigma, # R4643), respectively. After 72 hours incubation, the cells were washed and 
harvested in the reporter lysis buffer, and luciferase and protein measurements were 
performed, according to the protocol (Protocol 6). 
Protocol 5 
Solutions 
2 x Hepes-buffer-saline (2 x HBS) 
1.6 g NaCl, 0.074 g KCl, 0.024 g Na2HPO4x 2H2O, 0.2 g dextrose, 1 g hepes. 
Dissolve in ddH20 to a total volume of 100 ml and adjust to pH 7.05. Sterilize by 
filtration (0.2μm in diameter). 
CaCl2 (250 mM) 
3, 676 g CaCl2 x 2H20. Dissolve in ddH20 in a total volume of 100 ml. Sterilize by 
filtration (0.2μm in diameter).  
10 x PBS 
1 tablet (Gibco, # 18912-014)) in 10 ml H20. Sterilize by filtration (0.2μm in 
diameter). 
2xHBS/PBS 
10 μl 10xPBS/ml 2xHBS  
Ligands 
Ligands, 10 μM Wy 14.463 and 1 μM 9-cis-RA dissolved in DMSO, were added to 
growth medium.  
Reporter Lysis 5 x buffer (Promega, # E397A) 
1x PBS 
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Experimental procedure 
Prepare the plasmids 
 Mix the plasmids in Falcon tubes (15 ml). Total amount of DNA to each well should 
be 10 μg: 5 μg of the reporter plasmid (pGL3-LSDP5(-2324/+244)luc), 1 ug of each 
of the expression plasmids (pSG5-hERRα, pSG5-mPPARα, pSG5mRXRα or 
pSG5m-PGC-1α ). Regulate with empty vector to obtain the correct amount DNA 
(Table 1).  
Stimulation with ligands 
Seed the cells in six-well plates, and allow them to grow overnight. Remove medium 
from the cells. Add control medium or medium with ligands (10 μM PPARα and 1 
μM 9-cis-RA), 3 ml/well, prior to the transfections.   
Transfection 
Mix 2 x HBS and 10 x PBS in a Falcon tube. Transfer (250 μl) of this mix to the 
tubes with plasmids. Vortex in at least 20 seconds. During vortexing, add (250 μl) 
calcium chloride in droplets. This will result in formation of an insoluble calcium 
phosphate coprecipitate with DNA. Add (500 μl) of the transfection mix to each well 
(Table 1). The coprecipitate will now attach to the cells and uptake by endocytosis 
will take place. Incubate for 72 hours, 37°C.  
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  Reporter plasmid (LSDP5-luc) 5 μg    
  
Expression plasmids (PPARα, RXRα, ERRα or PGC-
1α) 1-4 μg    
  Empty vector to 10μg    
  Tot 10 μg     
      
  2xHBS/10xPBS 250 μl    
  CaCl2 250 μl    
  Tot (mix) 500 μl     
      
        
Table 1:  Plasmids and transfection mix given to each well in a six-well plate. Each well was added 3 
ml medium +/- ligand prior to the transfection mix and plasmids. 
 
 
Harvesting and lysis  
Remove growth medium from the cells. Wash the cells with 1x PBS twice. Add 200 
ul 1 x lysis buffer to each well. Incubate for 15 minutes at room temperature. Scrape 
attached cells from the dish, and transfer them to tubes on ice. Store the tubes in the 
freezer at -20°C, or continue with luciferase and protein measurements.  
3.2.7 Luciferase activity- and protein measurements 
The Luciferase Assay 
The Luciferase assay is commonly used in many laboratories. The purpose of this 
reporter assay is to measure the regulatory potential of an unknown DNA-sequence. 
This can be done by linking a promoter sequence to an easily detectable reporter 
gene. Luciferase serves as an excellent reporter gene in promoter analysis studies. 
Most luciferase marker genes currently in use are derived from the luciferase gene of 
the the firefly (Photinus pyralis). Luciferase is an enzyme, which acts as a reporter by 
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emitting light during oxidation of their chemical substrate, luciferin. The firefly 
luciferase catalyzes the bioluminescent oxidation of the luciferin in the presence of 
ATP, magnesium and oxygen (Figure 3.3). The light generated during this process is 
captured, amplified and measured in a luminometer. The assay provides accurate 
measurements of the level of gene expression (98). Thus, measuring luciferase 
activity is a good strategy to study transcriptional activity in the promoter of a gene.  
 
 
 
 
 
Figure 3.3: The principle of Luciferase Assay 
 
Luciferase activity measurement 
After cells were harvested, luciferase activity was measured according to the protocol 
(Protocol 6). Prior to the measurements, cells were mixed by vortexing and then 
centrifuged. The supernatant was used to the luciferase measurements.   
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Protein concentrations measurement  
Luciferase activity was related to the protein concentrations in the cells. Protein 
concentrations were measured prior to luciferase activity, by using the BC Assay. 
This is a colorimetric protein assay based on a reaction where Cu2+ is reduced to Cu+ 
when bound to the peptidic bounds of proteins, leading to the formation of a water 
soluble purple coloured complex. The reaction is measured by the high optical 
absorbance of the final Cu+ complex at 562 nm. Absorbance is directly proportional 
to the protein concentration, which can be calculated with a reference curve obtained 
for a standard protein (Appendix, Protocol 7). 
 
Protocol 6 
Solutions 
Luciferase assay reagent: 470 uM luciferin, 530 μM ATP, 270 μM coenzyme A, 20 
nM tricine, 3.74 mM MgSO4 x 7H2O, 0.1 mM EDTA, 33.3 mM DTT. Add 100 ml 
H2O. 
BC Assay Protein quantitation kit: reagent A, reagent B, Albumin standard 
Experimental procedure 
Protein measurement 
Vortex the cells in at least 20 seconds to mix the content carefully. Measure protein 
concentrations with the BC Assay method according to the manufacturers protocol 
(Appendix, Protocol 7). 
Luciferase activity 
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After protein concentrations are measured, centrifuge the samples at 4°C, 13 000 rpm 
for 2 minutes. Transfer 100 μl of the luciferase assay reagent into each luminometer 
tube. Then add 10 μl of each sample with cell lysate to a luminometer tube. Vortex 
before inserting the tube into the luminometer. Initate reading.  
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4. Statistical analysis 
The results from transfection studies are presented as means + SD, and are 
representative for three (four) individual experiments performed in triplicates. 
Due to the small sample size, a non-parametric method was used to examine 
statistical significance between independent samples. Statistically significance 
was set at 5 % (P<0.05).  
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5. Results 
The main objective in this project was to study the transcriptional regulation of 
LSDP5. Dalen et al.(101) demonstrated that LSDP5 is transcriptionally stimulated by 
activation of PPARα in mouse liver and heart. To study this, wild type and PPARα 
knockout mice were fed with vehicle (CMC) or a potent synthetic PPARα activator, 
WY 14.643, 10 mg/kg daily for one week. mRNA analysis from liver and heart 
tissues were performed, and a six-fold induction of the LSDP5 mRNA was found in 
the liver of wild type mice, compared to no induction in the PPARα knockout mice. 
The transcriptional regulation of LSDP5 by WY-14.643 feeding was much weaker in 
heart, with only a 1.3 fold induction of the LSDP5 mRNA. Furthermore, it was 
shown that PPARα is important for the basal expression of the LSDP5 gene both in 
liver and heart. In PPARα knockout mice, the basal expression of the LSDP5 gene 
was approximately 90 % lower in liver and 60 % lower in heart tissue, compared to 
wild type mice (102).  These findings suggest that transcriptional regulation of 
LSDP5 is dependent on a functional PPARα. 
So far, it has been difficult to show through transfection studies that the LSDP5 gene 
contains an evolutionarily conserved PPARα responsive DR-1 element. It has thus 
been necessary with more transfection studies to prove that PPARα regulates the 
transcription of the LSDP5 gene through a PPRE. In this project, the identification a 
possible PPRE and testing of its functionality was studied by cotransfecting a full-
length LSDP5 reporter construct with PPARα and RXRα expression vectors into 
Cos-1 cells.  To study this, transfected cells were treated with WY 14.643 and 9-cis-
retinoic acid to activate PPARα and RXRα, respectively. Since it previously in 
preliminary studies has been difficult to observe any transcriptional regulation of the 
LSDP5 gene by cotransfection with PPARα/RXRα alone, additional factors were 
included in this thesis to examine whether the regulation of this gene by 
PPARα/RXRα is dependent on other regulatory proteins.  
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Sub-objectives in this project were therefore to examine if the PPARα/RXRα 
mediated transcriptional regulation of LSDP5 is dependent on the NR ERRα and/or 
the coactivator PGC-1α. The reason why these proteins were included in the 
transfection assay is that both ERRα and PGC-1α are highly expressed in metabolic 
tissues, and they are known to be involved in the regulation of FA oxidation 
pathways. It is therefore likely that they cross-talk with PPARα/RXRα in the 
transcriptional regulation of the LSDP5 gene based upon what is known about the 
function of LSDP5. It is demonstrated that ERRα upregulates genes that are 
important regulators of FA oxidation in liver and most of them are known PPARα 
target genes (103). It is also shown that PPARα itself is a direct ERRα target gene 
(104). Furthermore, several studies indicate that PGC-1α is a potent coactivator of 
both ERRα (105-107) and PPARα (108;109) in transcriptional regulation of their 
target genes. It is thus likely that the PPARα mediated regulation of the LSDP5 gene 
might be affected by ERRα, and that PGC-1α might play an important role as a 
coactivator that enhances the expression of the LSDP5 gene.  
 
In order to study this, transfection studies were performed to investigate the effects of 
PPARα/RXRα, ERRα and PGC-1α on LSDP5 expression, both individually and in 
combination. Both full-length LSPD5 promoter (pGL3-(m)LSDP5-Luc [-2324 to 
+244]) construct, a deletion construct (pGL3-(m)LSDP5-Luc [-1329 to +244])  and a 
mutation construct (pGL3-(m)LSDP5-Luc [-2324 to +244-DR-1 mut])  were used to 
map the most PPARα -responsive region in the promoter of the LSDP5 gene. 
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5.1 PPARα alone gives no significant induction of the 
LSDP5 gene 
Firstly, the basal activity in the cells was examined; that means the transcriptional 
activity with only endogenously expressed receptors and ligands present. Further, the 
activity in these cells will be referred to as “control”. These cells were transfected 
with full-length LSDP5 promoter (pGL3-(m)LSDP5-Luc [-2324 to +244]) only, to 
measure the transcriptional activity in the LSDP5 gene, affected by endogenous 
ligands and transcription factors exclusively. The basal activity was compared to 
activity in cells which were stimulated with synthetic ligands for PPARα and RXRα, 
WY-14.643 and 9-cis-RA, respectively. Activation of endogenously expressed 
PPARα /RXRα by synthetic ligands resulted in a marginal (1.4-fold) induction of 
LSDP5, compared to control (Figure 6.1). When pGL3-(m)LSDP5-Luc [-2324 to 
+244]  was cotransfected with PPARα and RXRα to examine the effect of 
exogenously added PPARα/RXRα on transcriptional activity of the LSDP5 gene, I 
did not observe a consistent reporter gene activity. Whereas treatment with WY-
14.643 gave a 3.5-fold reporter gene activity in one experiment (Figure 6.2), PPARα 
activation resulted in only 0.8-fold induction in another experiment (Figure 6.3). 
These results indicate that PPARα/RXRα alone is not sufficient to give a significant 
transcriptional induction of the LSDP5 gene.  
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Figure 6.1: Basal activity in Cos-1 cells transfected with pGL3-(m)LSDP5-Luc [-2324 to +244] . 
Then the cells were treated with vehicle (DMSO) or ligand (10μM WY-14.643 and 1μM 9-cis-RA).  
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Figure 6.2: LSDP5 reporter vector cotransfected with none or RXRα and PPARα expression vectors. 
Then the cells were treated with vehicle (DMSO) or ligand (10μM WY-14.643 and 1μM 9-cis-RA).  
 
 
Figure 6.3: LSDP5 reporter vector cotransfected with none or RXRα and PPARα expression vectors. 
Then the cells were treated with vehicle (DMSO) or ligand (10μM WY-14.643 and 1μM 9-cis-RA).  
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5.2 PGC-1α enhanced the transcriptional activity of the 
LSDP5 gene 
Coactivator PGC-1α highly induced the transcriptional activity of the LSDP5 gene. 
The maximal effect was observed when exogenously expressed PPARα and RXRα 
were present in Cos-1 cells together with PGC-1α. 
Firstly, the full-length LSDP5 promoter (pGL3-(m)LSDP5-Luc [-2324 to +244]) was 
cotransfected with the expression plasmid of PGC-1α, to examine the effect of this 
co-activator on the transcriptional induction of the LSDP5 gene. Exogenously 
expressed PGC-1α present in the cells enhanced the reporter activity with 4.8-fold 
when cells were treated with WY-14.643. Without treatment, the activity was only 
marginally increased (1.3-fold) (Figure 6.4). 
Next, the full-length LSDP5 (pGL3-(m)LSDP5-Luc [-2324 to +244])  luc reporter 
construct was cotransfected with PPARα, RXRα and PGC-1α expression vectors. 
Activation by WY-14.643 in these cells resulted in 17-fold induction of the reporter 
gene (Figure 6.4). 
Despite there was a certain level of variation in luciferase values between the four 
experiments, it was possible to observe a clear trend, indicating the enhanced co-
activator effect of PGC-1α, through PPARα/RXRα in the LSDP5 promoter gene, 
measured by increased reporter gene activity (Figure 6.5). All experiments 
demonstrated that the presence of PGC-1α along with exogenously expressed PPARα 
and RXRα resulted in a high transcriptional activity of LSDP5.  
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Figure 6.4: LSDP5 reporter vector cotransfected with none, PGC-1α- or RXRα and PPARα 
expression vectors in Cos-1 cells. Then the cells were treated with vehicle (DMSO) or ligand (10μM 
WY-14.643 and 1μM 9-cis-RA).  The result is representative of four individual experiments 
performed in triplicates. Results are given as mean + SD. (None, vehicle = 1). 
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Figure 6.5: Four transfection experiments with LSDP5 reporter vector cotransfected with none, 
PPARα/RXRα, PGC-1α and PPARα/RXRα/PGC-1α in Cos-1 cells. The figure shows only stimulated 
cells (10μM WY-14.643 and 1μM 9-cis-RA). Results are given as mean + SD. (None, vehicle = 1). 
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5.3  ERRα downregulated the expression of LSDP5 
Surprisingly, full length LSDP5 pGL3-(m)LSDP5-Luc [-2324 to +244]) luc reporter 
cotransfected with ERRα resulted in remarkable low induction of LSDP5. There was 
almost no difference between stimulated (0.5-fold induction) and unstimulated (0.4-
fold induction) cells (Figure 6.6).  
LSDP5 luc reporter cotransfected with ERRα, PPARα and RXRα expression vectors 
reduced the induction of LSDP5 compared to control. Treatment with WY-14.643 
gave a 0.9-fold reporter gene activity. 
When full length LSDP5 luc construct was cotransfected with PGC-1α  in addition to 
ERRα, PPARα and RXRα, and stimulated with WY-14.643, the induction of luc 
activity  increased 7.0-fold. This indicates that PGC-1α strongly upregulates the 
expression of LSDP5, which is consistent with the previous results. However, it 
seems like the effect of PGC-1α is reduced (from 17-fold to 7.0 fold) when ERRα is 
coexpressed in the cells.  
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Figure 6.6: LSDP5 reporter vector cotransfected with none-, PPARα/RXRα, PGC-1α, 
PPARα/RXRα/PGC-1α, ERRα, PPARα/RXRα/ERRα or PPARα/RXRα/ERRα/PGC-1α expression 
vectors in Cos-1 cells. Then the cells were treated with vehicle (DMSO) or ligand (10μM WY-
14.643 and 1μM 9-cis-RA). Results are given as mean + SD. (None, vehicle = 1). 
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5.4 The LSDP5 promoter contains an evolutionarily 
conserved PPAR responsive DR-1 element 
The transcriptional regulation of LSDP5 was expected to be mediated through a 
PPRE (DR1). To map the most PPARα-responsive region in the LSDP5 promoter, 
one 5’- deletion construct made by Post.doc. Knut Tomas Dalen (Figure 6.7) was 
transiently transfected into COS-1 cells together with the expression plasmids 
decribed earlier. Since the previous results demonstrated that exogenously expressed 
PGC-1α in combination with PPARα and RXRα strongly elevated the induced 
expression of the LSDP5 gene, PPARα, RXRα and PGC-1α expression vectors were 
cotransfected with the LSDP5 deletion construct (pGL3-(m)LSDP5-Luc [-1329 to 
+244]). There was no significant reporter activity using this LSDP5 reporter plasmid, 
compared to a 9-fold induction of reporter activity using the wild type (WT) LSDP5  
(pGL3-(m)LSDP5-Luc [-2324 to +244]) promoter (Figure 6.8). These results indicate 
that the promoter region from -2324 bp to -1329 bp upstream from the transcriptional 
start site might contain a DR1 element that mediates PPARα transcriptional 
regulation of the LSDP5 gene.   
 One 5`- mutation construct (pGL3-(m)LSDP5-Luc [-2324 to +244-DR-1 mut]) 
(fig.6.4A), also made by Knut Tomas Dalen, was cotransfected into Cos-1 cells. The 
mutation was performed by “site directed mutagenesis” where one nucleotide in each 
half site is mutated, resulting in a DR1 element that is not recognizable for the 
PPARα and thereby leads to no PPARα activation. Cotransfection with the mutated 
construct did not induce reporter activity (Figure 6.9).  This finding confirms that the 
LSDP5 promoter region from -2324 bp to -2064 bp upstream from transcriptional 
start site might contain a conserved PPAR response DR-1 element, and that this DR-1 
element more specifically is located in the -2077 to -2064 upstream region in the 
LSDP5 promoter. 
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Figure 6.7: The LSDP5 constructs that were transfected into Cos-1 cells: one full-length construct 
(M12-1), one deletion construct (M12-2) and one mutation construct (M12-4). 
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Figure 6.8: Full length LSDP5 (pGL3-(m)LSDP5-Luc [-2324 to +244]) promoter construct (WT) 
and a LSDP5 deletion construct (pGL3-(m)LSDP5-Luc [-1329 to +244]) cotransfected with none-, 
PPARα/RXRα, PGC-1α, PPARα/RXRα/PGC-1α, ERRα, PPARα/RXRα/ERRa or 
PPARα/RXRα/ERRα/PGC-1α expression vectors. The figure shows only stimulated cells (10μM 
WY-14.643 and 1μM 9-cis-RA). Results are given as mean + SD. (None, vehicle = 1). 
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Figure 6.9: Full length LSDP5 (pGL3-(m)LSDP5-Luc [-2324 to +244]) promoter construct (WT) 
and a mutation construct (pGL3-(m)LSDP5-Luc [-2324 to +244-DR-1 mut])   cotransfected with 
none-, PPARα/RXRα, PGC-1α, PPARα/RXRα/PGC-1α, ERRα, PPARα/RXRα/ERRa or 
PPARα/RXRα/ERRα/PGC-1α expression vectors. The figure shows only stimulated cells (10μM 
WY-14.643 and 1μM 9-cis-RA). Results are given as mean + SD. (None, vehicle = 1). 
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6. Discussion 
6.1 Methodology 
The main focus in this thesis was to examine whether PPARα, through a PRRE 
(DR1) in the LSDP5 promoter, regulates the expression of the LSDP5 gene. 
Transfection studies are frequently used for this purpose. By transfecting the reporter 
plasmid (pGL3-(m)LSDP5-Luc [-2324 to +244) into Cos-1 cells, it is possible to 
analyze the transcriptional activity of this particular gene after cotransfection with 
different expression plasmids as described earlier. Then expression plasmids might be 
added one at the time or combined, to examine their effect on the reporter activity. 
Thus, transfection studies give important information about the transcriptional 
activity in a particular gene. In this case, a LSDP5 promoter construct cloned into a 
luciferase reporter vector and PPARα, RXRα, ERRα and PGC-1α expression 
plasmids, were used to study their influence on the transcriptional activity of the 
LSDP5 gene. 
All data presented in this thesis are based on in vitro experiments. The transfection 
method is an important tool to study the transcriptional activity in a particular gene. 
However, there are also limitations related to this method. Transfection studies alone 
give no information of mRNA or protein expression in distinct tissues or how a 
protein is regulated upon physiological conditions, compared to in vivo studies. In 
vivo studies and in vitro studies combined are required to obtain a complete picture of 
how a gene is transcriptionally regulated. Prior to this thesis, in vivo experiments with 
knockout mice had shown that LSDP5 expression in liver and heart was dependent 
on a functional PPARα. Transfection studies were needed to confirm that the LSDP5 
gene is transcriptionally regulated by PPARα through a specific PPARα response 
element.  
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The transfections in this thesis were performed by the calcium phosphate 
precipitation method. I will further discuss advantages and limitations of this method. 
The calcium phosphate precipitation method is a well established transfection method 
that has been used for 30 years. The principle behind this method is the formation of 
a calcium phosphate precipitate that occurs in supersaturated solutions. The forming 
precipitate binds DNA and the complex of calcium phosphate and DNA is absorbed 
by the cells. Despite a rapidly growing choice of efficient transfection reagents, this 
method remains highly attractive. It is a significant goal to achieve high degree of 
transfection efficiency when performing a transfection. Although a wide range of 
conditions will lead to precipitates, high transfection efficiencies are only obtained 
within a narrow range of optimized parameters that assure certain properties of the 
precipitate (110). These parameters will be discussed in more detail in the following 
section. 
The calcium concentration influences the formation of precipitates. Calcium is 
present in the medium, in which cells are cultured. However, the concentration is kept 
low due to its poor solubility in the presence of phosphate and carbonate ions. 
Increased calcium concentration during transfection leads to spontaneously formation 
of microprecipitates, which is indicated to enhance the transfection efficiency.  
The precipitate of calcium and phosphate may undergo changes during transfection. 
The solubility of the precipitate is another parameter, which influences the efficiency 
of the transfection. Calcium phosphate precipitation is a dynamic and reversible 
process, and supersaturation of the solution favours the formation of precipitates. The 
main factors determining the supersaturation are the concentrations of calcium and 
phosphate. The pH also plays an important role, by influencing the solubility of 
phosphate, and should be kept at pH=7.05. In addition, temperature, DNA 
concentration and the degree of purity of the DNA affects the solubility. The fact that 
transfection efficiency highly depends on the characteristics of the solution, is one of 
the limitations with this method, since there are many factors that might influence the 
solution and thus affect the results in a negative manner. There are highly efficient 
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transfection reagents available today, which remain chemically stable and thus are 
easier to deal with. However, the calcium phosphate precipitation method works well 
when paying attention to the factors mentioned above. 
The formation of the calcium phosphate precipitate is affected by the DNA 
concentrations. At lower concentrations, DNA`s positive effect does not achieve its 
full potential, while at high concentrations the DNA can be detrimental to the 
precipitation. 25 μg DNA/ml is optimal concentration to obtain highest degree of 
transfection efficiency (111).  In my experiments 20 μg DNA/ml was used based on 
optimalizations prior to the experiments. 
It is crucial that the cells are in exponential growth phase when used in transfections, 
thereby increasing the transfection efficiency. The cells will undergo mitosis right 
after the transfection, and that results in nuclear entry of the DNA in the cells. When 
adherent cells are kept subconfluent, it allows one more doubling. In my experiments, 
cells were seeded at 90 % confluency the day before transfection. 
The efficiency of transient transfection is determined largely by the cell line that is 
used. Different lines of cultured cells vary by several orders of magnitude in their 
ability to take up and express exogenously added DNA. It is also important that the 
cells do not express the expression vectors of interest. In my transfections adherent 
Cos-1 cells were used. This cell line is known as an especially suited host for 
transfections due to its low expression of transcription factors that might influence the 
expression of the gene of interest. 
One of the challenges in using the calcium phosphate precipitate method is to avoid 
cytotoxicity. Calcium phosphate precipitates are cytotoxic in a dose- and time-
dependent manner. Calcium present in the form of calcium precipitates may cause 
cell damage and cell death. Toxic effects can be avoided by limiting exposure time to 
the precipitate to a few hours.  
When the parameters mentioned above are optimized, the calcium phosphate 
precipitate method works well according to my experience. The main advantages are 
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that it is cheap and easy to perform. Beneficially, it is the only method without traces 
of synthetic chemical components, since only natural compounds are used. This has a 
positive influence on the viability of cells and for the quality and purity of the 
product. Limitations include the time consuming procedure, and the usage of large 
amounts of DNA. 
In addition to the calcium phosphate precipitation method, several other methods 
have been described to introduce DNA expression vectors into mammalian cells in 
vitro and in vivo and other transfection reagents can be used for this purpose. The 
calcium phosphate precipitation method includes the use of chemical reagents. 
Another chemical reagent that is available to use is DEAE-dextran, a cationic 
polymer that associates with negatively charged nucleic acids. An excess of positive 
charge contributed by the polymer in the DNA/polymer complex allows the complex 
to come closer into association with the negatively charged cell membrane. Uptake of 
the complex is presumably by endocytosis. This method suits particularly well for 
transient transfections.  
The use of artificial liposomes is a second alternative among chemical reagents, and 
Lipofectamine is a widely used transfection reagent today. Liposome-mediated 
nucleic acid delivery is based on the principle that the cationic portion of the lipid 
molecule associates with the negatively charged nucleic acids, resulting in a 
compaction of the nucleic acid in a liposome/nucleic acid complex. For cultured cells, 
an overall net positive charge of the liposome/nucleic acid complex generally results 
in higher transfer efficiencies, presumably because this allows closer association of 
the complex with the negatively charged cell membrane. Follwing endocytosis, the 
complexes appear in the endosomes, and later in the nucleus. Lipofectamine works 
with many primary cell lines and provides high transfection efficiency.    
 
 
 
 66 
6.2 General discussion 
LSDP5 is a recently identified member of the PAT family. The knowledge upon this 
protein is still limited. Nebb`s group has previously shown in animal studies that this 
protein is transcriptionally regulated by PPARα. However, it has been difficult to 
prove through transfection studies that this regulation is mediated through a PPARα 
response DR1 element. The main objective for this thesis was thus to establish 
whether there is a functional PPAR response element located in the LSDP5 promoter. 
Furthermore, the aims were to examine whether the transcriptional regulation of 
LSDP5 is affected by additional regulatory factors; the transcription factor ERRα and 
the coactivator PGC-1α. Our data confirms that LSDP5 contains a functional PPRE. 
The results also indicate that ERRα and PGC-1a are involved in the PPARα mediated 
regulation of LSDP5. 
Previous experiments have failed to prove that PPARα transcriptionally regulates the 
LSDP5 gene through a conserved PPRE. Neither this study showed any consistent 
induction of LSDP5 mediated by PPARα, when we studied the isolated effect of 
PPARα. Since previous results have shown that the expression of LSDP5 in liver and 
heart is dependent on a functional PPARα, it is still likely that PPARα regulates the 
expression of LSDP5, however the full picture of this regulation is not completely 
understood. Based on these observations, we hypothesized that the regulation of 
LSDP5 might be affected by ERRα and PGC-1α, since it is well known that they play 
an important role in controlling the expression of genes that play a major role in FA 
oxidation pathways in metabolic tissues, like the liver and skeletal muscle. 
In our transfection studies we found that PGC-1α strongly enhanced the 
transcriptional activity of the LSDP5 gene together with PPARα/RXRα after Wy-
14.643 stimulation of Cos-1 cells. These results indicate that this co-activator is an 
important regulator of the expression of LSDP5, and that it mediates its action by an 
interaction with PPARα through a PPRE in the LSDP5 promoter. These findings are 
consistent with emerging knowledge of PGC-1α. PGC-1α is known as a potent 
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activator with a powerful transcriptional activity, which interacts with most members 
of the NR family, including PPARα (112). The close relationship between PPARα 
and PGC-1α is illustrated by the fact that they both are co-expressed in tissues with a 
high FA oxidation activity such as heart, liver and BAT. Furthermore, it is confirmed 
that there is a direct link between PGC-1α and PPARα. PGC-1α coactivates PPARα 
in the transcriptional regulation of FA oxidation genes. This was demonstrated in 
protein-protein interaction studies, performed by Vega and collaborators (113). They 
demonstrated that PGC-1α physically interacts with PPARα and that the PGC-1α-
PPARα interaction involves an LXXLL domain in PGC-1α and an AF3 region in 
PPARα. Furthermore, it was shown that PGC-1α binds PPARα in a ligand-dependent 
manner (114).  This is consistent with my results, where I observed a maximal 
transcriptional activation of the LSDP5 gene after stimulation with the PPARα 
ligand. PGC-1α was originally identified as a PPARγ interacting protein. 
Interestingly, PGC-1-PPARγ interaction is independent on ligand activation.  
Dalen and colleges showed that LSDP5 is highly induced in heart during fasting 
(115). Both PPARα and PGC-1α play an important role in a fasting response, by 
regulating the expression of genes involved in FA oxidation. Despite that it is found 
that induction of the LSDP5 expression is independent on a functional PPARα, it is 
observed that presence of PPARα facilitates the expression of LSDP5 during fasting. 
PGC-1α is induced in a tissue-specific manner by signals that represent metabolic 
needs. One of these signals is starvation, resulting in a marked increase of PGC-1α in 
liver and heart. The role of PGC-1α in liver is to regulate the metabolic changes that 
occur in the liver during fasting, such as activation of gluconeogenesis, FA oxidation 
and synthesis and secretion of ketone bodies. These changes facilitate a shift from the 
usage of glucose to fats and ketone bodies by peripheral tissues, to ensure that 
glucose levels are maintained. PGC-1α mediates its regulation by coactivating key 
hepatic transcription factors such as HNF4α, PPARα, GR, FOXO1, FXR and LXR. 
Based on my observations, the current knowledge of PGC-1α and the fact that PGC-
1α and LSDP5 are coexpressed in liver and heart during fasting, is it reasonable to 
hypothesize that PGC-1α might regulate the expression of LSDP5 during fasting, by 
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coactivating PPARα. To our knowledge, no studies have investigated this so far, and 
further studies are needed to support these findings. It is of significant interest to 
examine whether the expression of LSDP5 is reduced in mice lacking a functional 
PGC-1α protein.  
When we examined the influence by the transcription factor ERRα, we found that the 
LSDP5 transcriptional activity in the cotransfection studies described in “Results” to 
be clearly reduced. This was a bit unexpected, since ERRα is highly coexpressed with 
PPARα and PGC-1α in tissues with high capacity of FA oxidation. Furthermore, 
ERRα is induced in liver during fasting, similar to PPARα, PGC-1α and LSDP5 
(116). However, ERRα has previously been reported both as an activator, a repressor 
and a DNA-binding factor with little activity (117). Whereas it is reported that ERRα 
activates several genes in FA oxidation pathways, it is demonstrated that ERRα 
represses the induction of other genes such as the gene encoding phosphoenol-
pyruvate carboxykinase (PEPCK), one of the rate-determining gluconeogenetic 
enzymes. These findings demonstrate that ERRα decreases the level of genes 
involved in gluconeogenesis in a fed state, by antagonizing the stimulatory effects of 
PGC-1α (118). The same mechanisms may underlie the observations from my 
experiments; that ERRα represses the induction of LSDP5, by antagonizing the 
stimulatory effects of PGC-1α. It is not fully understood how ERRα regulates the 
PEPCK gene expression, but it is possible that ERRα binds to a DNA response 
element of the PEPCK promoter called gAF3 (119). Bound to this DNA element, 
ERRα fails to cooperate properly with adjacent transcription factors as well as 
prevents the binding of another factor, perhaps a NR that promotes the formation of a 
transcriptionally active and PGC-1α responsive complex. Alternatively, ERRα bound 
at the gAF3 sequence may actively recruit co-repressors (120). However, according 
to our data the induction of LSDP5 was lower when PGC-1α was not present in the 
cells. Thus, it is possible that the repression by ERRα might be independent on PGC-
1α, and that it is mediated through other mechanisms. These results indicate that 
ERRα represses the expression of LSDP5, but future studies are needed to study the 
mechanisms that underlie this repression.  
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Taken together, our data confirmed that LSDP5 contains a conserved PPRE. The 
enhancing effect of PGC-1α on LSDP5 induction was studied in three LSDP5 
reporter constructs; one mutation and one deletion construct as well as a full-length 
promoter construct. Since I had already observed that LSDP5 was highly induced 
with exogenously expressed PGC-1α in combination with PPARα and RXRα, these 
three expression constructs were cotransfected with the distinct reporter constructs 
into the Cos-1 cells. Only the full length promoter construct showed a significant 
induction of LSDP5, suggesting that this promoter contains a DNA response element 
to which PPARα might bind and activates LSDP5 transcription. Collectively, my data 
and the recently published results of LSDP5 as a protein which expression is induced 
by the PPARα ligand (121;122), suggest that LSDP5 is a PPARα target gene.  
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6.3 Conclusion 
The newly discovered PAT protein LSDP5 is highly expressed in liver, red muscle 
and heart, and plays an important role during fasting. 
In this master thesis I have showed that; 
• LSDP5 is transcriptionally regulated by PPARα, through a conserved PPAR 
DR-1 element, located in the -2077 to -2064 upstream region in the LSDP5 
promoter. 
• The PPARα mediated regulation of LSDP5 is dependent on PGC-1α. The 
presence of this coactivator enhanced the induction of LSDP5 remarkably.  
• ERRα represses the expression of LSDP5. ERRα present reduces the 
enhancing effect of PGC-1α on LSDP5 induction. Further studies are needed, 
to investigate the mechanisms that underlie the inhibitory effect of ERRα. 
6.3.1 Future perspectives 
It would be of interest to pursue further studies to investigate the influence of PGC-
1α and ERRα on the expression of LSDP5. Studies with PGC-1α -/- mice are 
necessary to study whether the expression of LSDP5 is reduced in mice lacking a 
functional PGC-1α. Experiments with ERRα knockout mice will contribute with 
important information of the effect of ERRα on the induction of LSDP5. ERRα and 
PGC-1α double knock-out studies would be a significant tool to study the possible 
interplay between ERRα and PGC-1α in the PPARα mediated regulation of LSDP5. 
An electrophoretic mobility shift assay (EMSA) has to be used to investigate whether  
nuclear extracted PPARα and RXRα proteins bind to the identified PPRE in the 
LSDP5 promoter. Search for an ERRα response element located in the LSDP5 
promoter will also be of interest to address through transfection and EMSA studies 
whether ERRα binds directly to the regulatory area of the LSDP5 gene. 
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